Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIV · Real-Time Price · USD
34.64
-0.07 (-0.20%)
Aug 31, 2026, 4:00 PM EDT - Market closed
Roivant Sciences Employees
Roivant Sciences had 721 employees as of March 31, 2026. The number of employees decreased by 29 or -3.87% compared to the previous year.
Employees
721
Change (1Y)
-29
Growth (1Y)
-3.87%
Revenue / Employee
$10,447
Profits / Employee
-$369,283
Market Cap
25.02B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 721 | -29 | -3.87% |
| Mar 31, 2025 | 750 | -158 | -17.40% |
| Mar 31, 2024 | 908 | 4 | 0.44% |
| Mar 31, 2023 | 904 | 41 | 4.75% |
| Mar 31, 2022 | 863 | 198 | 29.77% |
| Jun 30, 2021 | 665 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BeOne Medicines AG | 12,000 |
| BioNTech SE | 7,807 |
| Genmab | 3,119 |
| Jazz Pharmaceuticals | 2,890 |
| Incyte | 2,844 |
| Alnylam Pharmaceuticals | 2,500 |
| Insmed | 1,664 |
| Ascendis Pharma | 1,189 |
ROIV News
- 3 days ago - Roivant, Priovant launch newly approved rare disease drug Lisraya at $35,000 a month - Reuters
- 3 days ago - Roivant Sciences Transcript: FDA announcement - Transcripts
- 3 days ago - Roivant Sciences Press release: FDA announcement - Filings
- 3 days ago - Roivant Sciences Slides: FDA announcement - Filings
- 4 days ago - US FDA approves Roivant-Priovant's skin and muscle disease drug - Reuters
- 4 days ago - Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S. - GlobeNewsWire
- 4 days ago - Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S. - GlobeNewsWire
- 5 days ago - JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis - GlobeNewsWire